BridgeBio Pharma Announces Late-Breaking ESPE 2026 Presentation and Additional Data on Oral Infigratinib in Achondroplasia

BridgeBio Pharma will present findings on oral infigratinib for achondroplasia at the ESPE Meeting 2026 in Marseille.

Quiver AI Summary

BridgeBio Pharma, Inc. announced that it will present a late-breaking oral presentation at the Annual European Society for Paediatric Endocrinology Meeting 2026 in Marseille, showcasing the impact of oral infigratinib on medical complications associated with achondroplasia from the PROPEL 3 study. The presentation, led by Dr. Julie Hoover-Fong from Johns Hopkins University, is scheduled for September 9. Additionally, the company will share two posters and one e-poster focusing on the longer-term data for oral infigratinib in achondroplasia, an ongoing study in very young children, and research on hypochondroplasia. BridgeBio aims to address significant unmet needs in skeletal dysplasias through its investigational drug, which targets the underlying genetic causes of conditions like achondroplasia and hypochondroplasia.

Potential Positives

BridgeBio Pharma is showcasing important research on oral infigratinib at a prominent international event, indicating strong engagement with the medical community and potential for increased visibility in the biopharmaceutical field.
The late-breaking oral presentation and additional posters highlight ongoing commitment to addressing significant unmet medical needs in conditions like achondroplasia and hypochondroplasia, showcasing the company's dedication to impactful healthcare solutions.
Oral infigratinib represents an innovative therapeutic approach targeting the underlying causes of skeletal dysplasias, which could greatly improve health outcomes for affected patients and strengthen BridgeBio’s position as a leader in genetic condition therapies.

Potential Negatives

The press release presents oral infigratinib as investigational, indicating that it may not yet have proven clinical efficacy or safety, potentially undermining confidence among stakeholders.
The mention of ongoing studies like PROPEL I&T suggests that the company has not yet fully established effective treatments for achondroplasia, which may raise concerns about the company's pipeline and development timelines.
While providing extensive information on the conditions served, there is no concrete data or results shared from the late-breaking presentation or ongoing studies, which may not satisfy investor or stakeholder demand for clarity on product effectiveness.

FAQ

What is the focus of BridgeBio Pharma?

BridgeBio Pharma focuses on developing medicines for genetic conditions, including achondroplasia and hypochondroplasia.

Where will the PROPEL 3 study results be presented?

The PROPEL 3 study results will be presented at the Annual European Society for Paediatric Endocrinology Meeting in Marseille, France.

What is oral infigratinib?

Oral infigratinib is an investigational drug designed to inhibit FGFR3 signaling, targeting skeletal dysplasia conditions like achondroplasia.

What medical complications are associated with achondroplasia?

Achondroplasia can lead to medical complications such as obstructive sleep apnea, spinal stenosis, and middle ear dysfunction.

How does BridgeBio address genetic condition treatment gaps?

BridgeBio utilizes a decentralized model enabling rapid development and commercialization of treatments for small patient populations.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$BBIO Insider Trading Activity

$BBIO insiders have traded $BBIO stock on the open market 61 times in the past 6 months. Of those trades, 0 have been purchases and 61 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:

NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 44 sales selling 311,083 shares for an estimated $22,422,909.
JENNIFER E. COOK has made 0 purchases and 6 sales selling 278,192 shares for an estimated $21,920,434.
ANDREA ELLIS has made 0 purchases and 2 sales selling 82,088 shares for an estimated $5,653,329.
HANNAH VALANTINE has made 0 purchases and 3 sales selling 13,675 shares for an estimated $965,835.
RANDAL W. SCOTT has made 0 purchases and 4 sales selling 10,000 shares for an estimated $671,455.
MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $303,280.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BBIO Congressional Stock Trading

Members of Congress have traded $BBIO stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 4 purchases worth up to $60,000 on 05/11, 04/29, 03/19, 03/18 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BBIO Hedge Fund Activity

We have seen 259 institutional investors add shares of $BBIO stock to their portfolio, and 258 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. removed 3,920,601 shares (-27.6%) from their portfolio in Q2 2026, for an estimated $292,006,362
WELLINGTON MANAGEMENT GROUP LLP added 2,824,971 shares (+113.7%) to their portfolio in Q2 2026, for an estimated $210,403,840
BROOKLANDS FUND MANAGEMENT LTD removed 2,750,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $204,215,000
CITADEL ADVISORS LLC added 2,475,758 shares (+354.6%) to their portfolio in Q1 2026, for an estimated $183,849,789
JPMORGAN CHASE & CO added 2,397,995 shares (+inf%) to their portfolio in Q2 2026, for an estimated $178,602,667
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,075,272 shares (-54.6%) from their portfolio in Q2 2026, for an estimated $154,566,258
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,900,000 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $141,512,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BBIO Analyst Ratings

Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/10/2026

To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.

$BBIO Price Targets

Multiple analysts have issued price targets for $BBIO recently. We have seen 9 analysts offer price targets for $BBIO in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Salim Syed from Mizuho set a target price of $96.0 on 06/16/2026
Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 06/03/2026
Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 05/28/2026
Sean Laaman from Morgan Stanley set a target price of $98.0 on 05/28/2026
Eric Joseph from Citigroup set a target price of $82.0 on 05/19/2026
Cory Kasimov from Evercore ISI Group set a target price of $130.0 on 05/08/2026
Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026

Full Release

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one late-breaking oral presentation on the impact of oral infigratinib on medical complications in achondroplasia from PROPEL 3 will be shared at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place in Marseille, France on September 8-10, 2026.

In addition to the late-breaking oral presentation, two posters and one eposter will be shared on longer-term data for oral infigratinib in achondroplasia, PROPEL I&T–an ongoing Phase 2/2b study in children under 3 years old with achondroplasia, and qualitative research on the impacts of hypochondroplasia.

BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia and other skeletal dysplasia conditions, which hold significant unmet needs for families.

Late-Breaking Oral Presentation:
A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study
Presenter: Julie Hoover-Fong, M.D., Ph.D., Johns Hopkins University, U.S.
Date: Wednesday, September 9 at 10:00 am CEST

Posters:
Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia
Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK

PROPEL Infant and Toddler: Study Design and Ongoing Enrollment of a Phase 2/2b Study of Infigratinib in Children under 3 Years Old with Achondroplasia
Presenter: Melita Irving, M.D., Guy's and St Thomas' NHS Foundation Trust, London, UK

ePoster:
Potential Medical Challenges and Functional Impacts of Hypochondroplasia: Qualitative Interviews with Children and Parents
Presenter: Melita Irving, M.D., Guy’s and St Thomas’ NHS Foundation Trust, London, UK

About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating variant in FGFR3.

About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok .

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]